What is the target price for curis?
Their forecasts range from $15.00 to $24.00. On average, they anticipate Curis' stock price to reach $19.80 in the next year. This suggests a possible upside of 323.1% from the stock's current price. View analysts' price targets for Curis or view top-rated stocks among Wall Street analysts. Who are Curis' key executives?
Does Curcuris (Cris) stock deliver strong earnings and revenue surprises?
Curis (CRIS) delivered earnings and revenue surprises of 7.69% and 14.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
How far away is curis stock from its 52-week low?
According to the current price, Curis is 140.64% away from the 52-week low. What was the 52-week high for Curis stock? The high in the last 52 weeks of Curis stock was 9.03.
Should you buy curis (Cris) stock on Hammer charts?
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately. Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
Is Curis stock a good buy?
Curis has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Will Curis stock recover?
The Wall Street analyst predicted that Curis's share price could reach $10.00 by Apr 5, 2023. The average Curis stock price prediction forecasts a potential upside of 800.9% from the current CRIS share price of $1.11.
Why is Curis stock up?
Curis stock more than triples on massive volume after upbeat leukemia treatment trial results. Shares of Curis Inc. more than tripled Tuesday, to lead all premarket gainers and with the most volume, after the biotechnology company announced positive preliminary data from a Phase 1 study of its leukemia treatment.
What is the long range forecast for CRIS stock?
Based on our forecasts, a long-term increase is expected, the "CRIS" stock price prognosis for 2027-07-21 is 6.526 USD. With a 5-year investment, the revenue is expected to be around +493.24%. Your current $100 investment may be up to $593.24 in 2027.
Will Curis go up?
Curis Inc (NASDAQ:CRIS) The 4 analysts offering 12-month price forecasts for Curis Inc have a median target of 11.50, with a high estimate of 22.00 and a low estimate of 4.00. The median estimate represents a +913.22% increase from the last price of 1.14.
Is CEI a good investment?
CEI has an overall F rating, which equates to a Strong Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree. CEI has an F grade for Value, Stability, and Quality.
Should I buy or sell Curis stock right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 1 hold ratin...
What is Curis' stock price forecast for 2022?
4 brokerages have issued twelve-month price objectives for Curis' shares. Their forecasts range from $4.00 to $20.00. On average, they predict Curi...
How has Curis' stock performed in 2022?
Curis' stock was trading at $4.76 at the start of the year. Since then, CRIS stock has decreased by 80.0% and is now trading at $0.95. View the be...
When is Curis' next earnings date?
Curis is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Curis .
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported ($0.18) earnings per shar...
When did Curis' stock split? How did Curis' stock split work?
Curis shares reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned b...
Who are Curis' key executives?
Curis' management team includes the following people: Mr. James E. Dentzer , Pres, CEO & Director (Age 55, Pay $990.03k) ( LinkedIn Profile ) Mr...
Who are some of Curis' key competitors?
Some companies that are related to Curis include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceutic...
What other stocks do shareholders of Curis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD) , Celldex Ther...
How many shares of Curis stock are there after the split?
What is Curis stock worth in 2020?
An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.
How much does Curis make?
Curis' stock was trading at $1.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRIS shares have increased by 606.4% and is now trading at $7.70. View which stocks have been most impacted by COVID-19.
How many research reports has Curis been subject to?
How much money does Curis make? Curis has a market capitalization of $704.82 million and generates $10.84 million in revenue each year. The biotechnology company earns $-29,910,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.
What is the NASDAQ symbol for Curis?
Curis has only been the subject of 1 research reports in the past 90 days.
What is the P/E ratio of Curis?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
What is the average rating of Curis?
The P/E ratio of Curis is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is small cap stock?
Curis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Is Curis a cancer company?
It’s the basic arithmetic behind finding a solid return potential. A small cap stock, one with a market value lower than $2 billion, will usually feature a relatively low share price – and when share price is low, even a small gain in absolute terms will quickly translate into a high-percentage return. Some
Is the Options Market Predicting a Spike in Curis (CRIS) Stock?
Curis (NASDAQ: CRIS), a small-cap cancer specialist, posted a healthy gain in August. Curis' shares appeared to be a direct beneficiary of Pfizer's (NYSE: PFE) buyout of Trillium Therapeutics (NASDAQ: TRIL), another small-cap cancer company with an early-stage pipeline. Curis' shares were essentially trading sideways during the early part of the month, but they quickly came to life in the aftermath of Pfizer's acquisition of Trillium on Aug. 23.
Is Curis oversold?
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Should I Avoid Curis, Inc. (CRIS)?
Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
58 Biggest Movers From Yesterday
Is Curis, Inc. (NASDAQ:CRIS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. ]
33 Stocks Moving In Thursday's Mid-Day Session
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active.
What is Curis Inc?
Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active.
What is market cap?
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Does market cap include convertible securities?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
Recently Viewed Tickers
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Curis Inc
Visit a quote page and your recently viewed tickers will be displayed here.